Active Pharmaceutical Ingredients

Catalog ID80017151

CAS NO.129618-40-2

Purity 98%

MDL NumberMFCD00866928

EINEC Molecular FormulaC15H14N4O

Molecular Weight266.2979

Melting point: 247~250°C

Aspect	Details
Mechanism of Action	Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds to the catalytic site of HIV-1 reverse transcriptase, inhibiting both RNA- and DNA-dependent DNA polymerase activities. It prevents viral RNA from being transcribed into DNA, thereby blocking viral replication.
Clinical Applications	It is primarily used to treat HIV-1 infection in adults and children, often as part of a combination antiretroviral therapy to reduce viral load, enhance immune function, and delay disease progression. It is also used to prevent mother-to-child transmission of HIV.
Pharmacokinetics	Metabolized mainly via the cytochrome P450 system, particularly CYP3A enzymes. It induces its own metabolism, leading to an increase in clearance and a decrease in plasma half-life from approximately 45 hours after a single dose to about 25–30 hours after multiple doses.
Resistance Development	Resistance can occur due to mutations in the reverse transcriptase gene, particularly at positions 181 and/or 106. These mutations can reduce the drug’s sensitivity by 100–250 times.
Storage Conditions	Should be stored in a cool, dry place, protected from light and moisture. For laboratory use, the powder form can be stored at -20°C for up to 3 years or at 4°C for up to 2 years. In solvent, it can be stored at -80°C for 6 months or -20°C for 1 month.
Side Effects	Common side effects include nausea, headache, fever, vomiting, diarrhea, and rash. Severe adverse reactions such as hepatotoxicity (including liver failure) and severe skin reactions like Stevens-Johnson syndrome can occur.
Formulations	Available as tablets and extended-release tablets. The extended-release form allows for once-daily dosing, improving patient convenience and adherence.
Research and Development	Originally approved by the FDA in 1996, it remains a cornerstone in HIV treatment regimens. Ongoing research focuses on optimizing dosing regimens and exploring new formulations to enhance efficacy and reduce side effects.

Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.

If you're ready to take the next step, Leave your message below and we’ll reply soon. 20+ years of chemical manufacturing & export experience, a partner you can trust.